NO960487L - Transdermalt medikament leveringssystem med lav fluksinnretning - Google Patents

Transdermalt medikament leveringssystem med lav fluksinnretning

Info

Publication number
NO960487L
NO960487L NO960487A NO960487A NO960487L NO 960487 L NO960487 L NO 960487L NO 960487 A NO960487 A NO 960487A NO 960487 A NO960487 A NO 960487A NO 960487 L NO960487 L NO 960487L
Authority
NO
Norway
Prior art keywords
drug delivery
transdermal drug
low flux
delivery system
flux device
Prior art date
Application number
NO960487A
Other languages
English (en)
Norwegian (no)
Other versions
NO960487D0 (no
Inventor
Eric J Roos
Chia-Ming Chiang
Tsung-Min Hsu
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22300358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO960487(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Publication of NO960487D0 publication Critical patent/NO960487D0/no
Publication of NO960487L publication Critical patent/NO960487L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO960487A 1993-08-09 1996-02-06 Transdermalt medikament leveringssystem med lav fluksinnretning NO960487L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/104,414 US5554381A (en) 1993-08-09 1993-08-09 Low flux matrix system for delivering potent drugs transdermally
PCT/US1994/008883 WO1995004554A1 (en) 1993-08-09 1994-08-05 Low flux transdermal potent drug delivery system

Publications (2)

Publication Number Publication Date
NO960487D0 NO960487D0 (no) 1996-02-06
NO960487L true NO960487L (no) 1996-02-06

Family

ID=22300358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960487A NO960487L (no) 1993-08-09 1996-02-06 Transdermalt medikament leveringssystem med lav fluksinnretning

Country Status (13)

Country Link
US (1) US5554381A (de)
EP (1) EP0716615B2 (de)
JP (1) JPH09505554A (de)
AT (1) ATE309004T1 (de)
AU (1) AU679557B2 (de)
CA (1) CA2169164A1 (de)
DE (1) DE69434537T3 (de)
DK (1) DK0716615T4 (de)
ES (1) ES2249763T5 (de)
FI (1) FI960556L (de)
NO (1) NO960487L (de)
NZ (1) NZ271797A (de)
WO (1) WO1995004554A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
AU2746397A (en) * 1996-04-30 1997-11-19 Theratech, Inc. Transdermal administration of steroid hormones using diethanolamides of c12-c18 fatty acids as permeation enhancers
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19830651A1 (de) * 1998-07-09 2000-01-13 Lohmann Therapie Syst Lts Steroidhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE02715112T1 (de) * 2001-03-16 2007-04-19 Alza Corp., Mountain View Transdermales pflaster zur verabreichung von fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
KR101144026B1 (ko) 2002-08-09 2012-05-09 후소 야쿠힝 고교 가부시끼가이샤 여성 호르몬 함유 부착제
AU2003301576A1 (en) 2002-10-22 2004-05-13 Eisai Co., Ltd. Gene expressed specifically in dopamine-producing neuron precursor cells after termination of division
DE60204229T2 (de) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
JP4914826B2 (ja) * 2005-02-28 2012-04-11 久光製薬株式会社 経皮吸収製剤
US8287923B2 (en) * 2005-06-10 2012-10-16 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating immune disorders
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US8734413B2 (en) 2007-08-03 2014-05-27 Kimberly-Clark Worldwide, Inc. Packaged body adhering absorbent article
US7947027B2 (en) 2007-12-28 2011-05-24 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article
US8672911B2 (en) 2007-08-03 2014-03-18 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article
NZ584190A (en) * 2007-10-15 2012-09-28 Alza Corp Once-a-day replacement transdermal administration of fentanyl
EP2258396B1 (de) 2008-03-03 2017-09-06 Hisamitsu Pharmaceutical Co., Inc. Transdermal absorbierbares präparat
US11147722B2 (en) * 2008-11-10 2021-10-19 Kimberly-Clark Worldwide, Inc. Absorbent article with a multifunctional acrylate skin-adhesive composition
US10022468B2 (en) 2009-02-02 2018-07-17 Kimberly-Clark Worldwide, Inc. Absorbent articles containing a multifunctional gel
US20130017188A1 (en) 2009-07-31 2013-01-17 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
CA2794565C (en) 2010-04-08 2018-08-21 Emory University Substituted androst-4-ene diones
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
WO2012151474A2 (en) 2011-05-04 2012-11-08 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2543370A1 (de) 2011-07-06 2013-01-09 Georgia Health Sciences University Research Institute, Inc. Zusammensetzungen und Verfahren zur Behandlung des Herpes-simplex-Virus
US9364487B2 (en) * 2011-11-04 2016-06-14 Agile Therapeutics, Inc. Dermal delivery compositions and methods
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
EP3036226B1 (de) 2013-08-22 2020-01-08 The General Hospital Corporation Hemmer der humanen 12/15-lipoxygenase
US11382883B2 (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
EP3303286B1 (de) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center An rela von nf-kb anbindende verbindungen zur verwendung bei der behandlung von krebs
KR102123365B1 (ko) 2015-07-28 2020-06-16 바이옴 테라퓨틱스 리미티드 항박테리아 치료제 및 예방제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5300291A (en) * 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
CA2065311C (en) * 1989-09-08 2000-01-11 Chia-Ming Chiang Solid matrix system for transdermal drug delivery
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JPH04342532A (ja) * 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収貼付剤
IT1253265B (it) * 1991-11-25 1995-07-14 Rotta Research Lab Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.

Also Published As

Publication number Publication date
AU7556294A (en) 1995-02-28
ATE309004T1 (de) 2005-11-15
JPH09505554A (ja) 1997-06-03
EP0716615B1 (de) 2005-11-09
EP0716615A4 (de) 1997-06-11
NZ271797A (en) 1997-12-19
EP0716615A1 (de) 1996-06-19
CA2169164A1 (en) 1995-02-16
DE69434537T2 (de) 2006-07-20
NO960487D0 (no) 1996-02-06
US5554381A (en) 1996-09-10
DE69434537D1 (de) 2005-12-15
FI960556A7 (fi) 1996-03-11
FI960556L (fi) 1996-03-11
DK0716615T4 (da) 2009-12-14
FI960556A0 (fi) 1996-02-07
AU679557B2 (en) 1997-07-03
ES2249763T3 (es) 2006-04-01
DE69434537T3 (de) 2010-04-15
ES2249763T5 (es) 2010-02-01
WO1995004554A1 (en) 1995-02-16
EP0716615B2 (de) 2009-10-21
DK0716615T3 (da) 2006-02-20

Similar Documents

Publication Publication Date Title
NO960487D0 (no) Transdermalt medikament leveringssystem med lav fluksinnretning
FI951424A7 (fi) Styreeni-isopreenistyreeni-kopolymeeriin perustuva transdermaalinen matriisijärjestelmä estrogeenin ja/tai progestogeenin antamiseksi
GR3032512T3 (en) Sexual steroid-containing transdermal therapeutic systems
DK0663820T3 (da) Farmaceutisk tablet, som er i stand til at frigive ét eller flere lægemidler med forskellige frigivelseshastigheder
ITTO910907A0 (it) Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.
NZ316026A (en) A transdermal therapeutic system (a hormone patch) in which drugs are contained which are released into the skin comprising a backing film and a pressure sensitive adhesive
NZ524767A (en) Composition for the transdermal delivery of fentanyl
KR940013496A (ko) 경피투여시스템
DK0889723T3 (da) Transdermalt terapeutisk system med ringe tykkelse af administreringsareal og stor fleksibilitet samt fremgangsmåde til fremstilling heraf
DK0499348T3 (da) Ovulationshæmmende middel til hormonal kontraception
NO962663D0 (no) Fremgangsmåte for hormonell prevensjon
KR900015761A (ko) 경피성 단일체 시스템
IL111648A0 (en) Transdermal delivery device
PT98571A (pt) Dispositivos para a libertacao controlada que utilizam membranas polimerizadas interfacialmente e de processos para a sua preparacao
EP0312265A3 (en) Adhesive compositions, controlled release compositions and transdermal drug delivery device
NO914900L (no) Orale lav-oestrogen-kontraseptiver
NO986104D0 (no) Progesteron-anti-progesteron regimer
CA2114936A1 (en) Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones
PL313819A1 (en) Panel support, especially for facing panel and method of securing panels using such support
HUP9903340A2 (hu) Trimegeszton transzdermális adagolására szolgáló új eszköz, és eljárás előállítására
NO993435L (no) Transdermalt acetylsalicylsyre inneholdende terapeutisk system med forsterket resorpsjon
DK1848406T3 (da) Fast, penoral lægemiddelform til kontraception, der indeholder dienogest og ethynylestradiol
CA2242577A1 (en) Skin-adhering pharmaceutical preparation, in particular transdermal therapeutic system for the release of 17-.beta.-estradiol to the human organism
Saline Please note the following correction to Brain Res. Bull., Vol. 35, Nos. 516, 1994. In the article entitled,“The Effects of Selective Alpha-2 Adrenergic Agents on the Performance of Rats in by SirviG et al.(pp. 451-&S), Tables 1 and 2 should have appeared as follows
RU96118406A (ru) Средство для чрескожного применения, содержащее дезогестрел